Quinoline-Thiazolidinedione-2,4-Dione demonstrated strong antihyperglycemic and antihypertriglyceridemic activities in zebrafish models, supported by in silico validation.
Abstract
Background: Type 2 diabetes mellitus (T2DM) and hyperlipidemia are interrelated metabolic disorders that significantly increase cardiovascular risk. Thiazolidinediones are known insulin sensitizers, whereas quinoline derivatives possess diverse pharmacological activities. To explore their complementary activity, we designed a novel hybrid compound integrating a thiazolidinedione core with a quinoline moiety via a carbon spacer. Materials and Methods: The hybrid molecule was synthesized through a straightforward route and structurally confirmed by spectroscopic analyses. Zebrafish (Danio rerio) were employed as an in vivo model, with hyperglycemia induced by immersion in 100 mM glucose monohydrate for 12 days. Fish were divided into treatment groups receiving 20 or 80 mg/kg of the compound, alongside the controls. Biochemical parameters (glucose, triglycerides, insulin) and gene expression levels (NF-κB, ACOX1, ACCα) were assessed. In silico docking was conducted to predict molecular interactions. Results: Treatment with the hybrid compound significantly restored glucose, triglyceride, and insulin levels. High-dose administration suppressed NF-κB expression and normalized ACOX1 levels, while both low- and high-dose treatments downregulated ACCα compared with untreated hyperglycemic controls. Computational studies supported multitarget activity through predicted binding to PPAR-α and ACOX1. Conclusions: Quinoline-Thiazolidine-2,4-Dione demonstrated strong antihyperglycemic and antihypertriglyceridemic activities in zebrafish models, supported by in silico validation.
D1 and D5 can be regarded as promising lead compounds for the development of new antidiabetics acting via inhibition of carbohydrate-metabolizing enzymes, indicating their antihyperglycemic activity in vivo.
Mahendra Gowdru Srinivasa, Shreya Kanchan, D. S. et al.· Molecules· 0 citations
Type 2 diabetes mellitus (T2DM) is a metabolic disorder associated with persistent hyperglycemia and impaired glucose regulation. Inhibition of pancreatic α-amylase is an important approach for reducing carbohydrate digestion and controlling postprandial blood glucose levels. In this study, a new series of substituted...
Diabetes mellitus, particularly type 2 diabetes mellitus, remains a major metabolic disorder characterized by persistent hyperglycemia arising from insulin resistance, impaired insulin secretion, and progressive pancreatic β-cell dysfunction. Despite the availability of several glucose-lowering therapies, limitations a...
Rupa Mazumdar, Arvind Kumar, A. Singh et al.· Oriental Journal of Chemistr...· 0 citations
This study identifies PB-TZD3 as a promising lead compound and highlights the significance of N-substitution in optimizing thiazolidinedione derivatives for improved antidiabetic activity.
Nitin P. Jain, Usha N. Jain, D. Kawade et al.· Asian Journal of Chemistry· 0 citations
The hybrid 4k exhibited maximum inhibition of α-glucosidase enzyme with favorable binding interactions, suggesting this framework is a potential lead motif for future antidiabetic drug discovery.
Anshul Grover, V. Asati, Jayant Sindhu et al.· Future Medicinal Chemistry· 0 citations
The combined experimental and computational results demonstrate significant structure-activity relationships within the bis-oxadiazole scaffold, identifying compound 10 as a promising lead candidate for further optimization as a dual enzyme inhibitor for diabetes management.
Shoaib Khan, Tayyiaba Iqbal, B. N. Murtaza et al.· Future Medicinal Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.